GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc., a privately held company developing a new class of glycobiology-based therapies for a broad range of indications, today announced it has initiated a Phase 1 clinical trial for GMI-1070, its lead drug candidate for the treatment of vaso-occlusive crisis of sickle cell disease.
